Lonza Inc. Boots Out CEO as 2011 Profit Plunges

Published: Jan 26, 2012

Swiss drugs industry supplier Lonza (LONN.VX) (LONZ.SI) kicked out chief executive Stefan Borgas after profits for 2011 plunged by a third and said 2012 was set to pose further challenges because of the difficulties faced by pharmaceutical firms. The Basel-based group, which is battling currency headwinds and volatile raw material prices, said the board took the decision to replace Borgas in the last 48 hours. "CEOs have a responsibility to deliver on expectation and I think our company over the last few years has not fully lived up to the expectation," Lonza Chairman Rolf Soiron told a conference call on Wednesday. Lonza makes high-margin pharmaceutical ingredients for drugmakers like GlaxoSmithKline (GSK.L) and Abbott (ABT.N), and has moved back into specialty chemicals as it seeks to shield itself from the volatile pharmaceutical industry.

Back to news